blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3942934

EP3942934 - MCT4 INHIBITORS FOR TREATING DISEASE [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  29.07.2022
Database last updated on 12.08.2024
FormerThe application has been published
Status updated on  24.12.2021
Most recent event   Tooltip28.06.2024New entry: Renewal fee paid 
Applicant(s)For all designated states
Vettore, LLC
1700 Owens Street
Suite 515
San Francisco, CA 94110 / US
[2022/04]
Inventor(s)01 / PARNELL, Kenneth
San Francisco, CA 94110 / US
02 / MCCALL, John M
San Francisco, CA 94110 / US
 [2022/04]
Representative(s)Sagittarius IP
Marlow International
Parkway
Marlow SL7 1YL / GB
[N/P]
Former [2022/04]Bridle, Andrew Barry
Bridle
Intellectual Property Limited
6F Thomas Way
Lakesview Internat. Business Park
Canterbury, Kent CT3 4JZ / GB
Application number, filing date21191357.913.06.2016
[2022/04]
Priority number, dateUS201562174685P12.06.2015         Original published format: US 201562174685 P
[2022/04]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3942934
Date:26.01.2022
Language:EN
[2022/04]
Search report(s)(Supplementary) European search report - dispatched on:EP14.12.2021
ClassificationIPC:A01N43/56, C07D231/12, C07D401/06, C07D405/12, C07D409/04, C07D417/04, A61K31/415, A61P35/00
[2022/04]
CPC:
C07D231/12 (EP,IL,KR,US); A61K31/415 (EP,IL,KR,US); A61K31/4155 (EP,IL,KR,US);
A61K31/427 (EP,IL,KR,US); A61K31/4439 (EP,IL,KR,US); A61K31/5377 (EP,IL,KR,US);
A61K45/06 (EP,IL,KR,US); A61P35/00 (EP,IL,KR,US); C07D401/06 (EP,IL,KR,US);
C07D405/12 (EP,IL,KR,US); C07D409/04 (EP,IL,US); C07D417/04 (EP,IL,US);
A61K2300/00 (IL,KR) (-)
C-Set:
A61K31/4155, A61K2300/00 (US,EP);
A61K31/415, A61K2300/00 (EP,US);
A61K31/427, A61K2300/00 (US,EP);
A61K31/4439, A61K2300/00 (EP,US);
A61K31/5377, A61K2300/00 (US,EP)
(-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2022/35]
Former [2022/04]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  RS,  SE,  SI,  SK,  SM,  TR 
TitleGerman:MCT4-INHIBITOREN ZU BEHANDLUNG VON ERKRANKUNGEN[2022/04]
English:MCT4 INHIBITORS FOR TREATING DISEASE[2022/04]
French:INHIBITEURS DE MCT4 POUR LE TRAITEMENT DE MALADIES[2022/04]
Examination procedure26.07.2022Amendment by applicant (claims and/or description)
26.07.2022Examination requested  [2022/35]
26.07.2022Date on which the examining division has become responsible
Parent application(s)   TooltipEP16808515.7  / EP3307068
Fees paidRenewal fee
07.12.2021Renewal fee patent year 03
07.12.2021Renewal fee patent year 04
07.12.2021Renewal fee patent year 05
07.12.2021Renewal fee patent year 06
27.06.2022Renewal fee patent year 07
27.06.2023Renewal fee patent year 08
27.06.2024Renewal fee patent year 09
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[A]US2011003874  (GUGLIELMOTTI ANGELO [IT], et al) [A] 1-19 * example -; claim - *;
 [A]WO2013171317  (SANOFI SA [FR]) [A] 1-19 * page 83, line 5 - page 86, line 10; example -; claim - *;
 [A]WO2014195507  (UNIV CATHOLIQUE LOUVAIN [BE], et al) [A] 1-19* example -; claim - *;
 [A]  - JENDROSSEK VERENA ED - SU CHANGQING ET AL, "Targeting apoptosis pathways by Celecoxib in cancer", CANCER LETTERS, NEW YORK, NY, US, (20110222), vol. 332, no. 2, doi:10.1016/J.CANLET.2011.01.012, ISSN 0304-3835, pages 313 - 324, XP028545990 [A] 1-19 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.canlet.2011.01.012
 [A]  - GYÖRGY SZABO ET AL., "New Celecoxib Derivatives as Anti-Inflammatory Agents", J.MED.CHEM., (2008), vol. 51, pages 142 - 147, XP002786421 [A] 1-19 * the whole document *
 [A]  - RAGAVAN R V ET AL, "Synthesis and antimicrobial activities of novel 1,5-diaryl pyrazoles", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, ELSEVIER, AMSTERDAM, NL, vol. 45, no. 3, doi:10.1016/J.EJMECH.2009.12.042, ISSN 0223-5234, (20100301), pages 1173 - 1180, (20100209), XP026895888 [A] 1-19 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.ejmech.2009.12.042
by applicant   - MURRAY, C. M. et al., "Monocarboxylate transporter MCT1 is a target for immunosuppression", Nature chemical biology, (20050000), vol. 1, doi:10.1038/nchembio744, pages 371 - 376, XP055241382

DOI:   http://dx.doi.org/10.1038/nchembio744
    - The Biochemical Journal, (20100000), vol. 425, pages 523 - 530
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.